Long-Term Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: Follow-Up Data from a 3-Year Open-Label Extension Study
Titel:
Long-Term Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: Follow-Up Data from a 3-Year Open-Label Extension Study
Auteur:
Stone, Caroline J. Ahuja, Geeta Lopes Almeida Gomes, Lais Poroye, Joy Faden, Daniella Forman Xie, Lillian Feng, Rui White, Barbara Werth, Victoria P.